BFM
ALXN

Boothbay Fund Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Boothbay Fund Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-149
Closed -$1.34M – 1164
2020
Q1 		$1.34M Buy
+149
New +$14.6K 0.11% 231
2019
Q3 		– Sell
-96
Closed -$1.26M – 967
2019
Q2 		$1.26M Buy
+96
New +$12.4K 0.11% 223
2017
Q1 		– Sell
-3,200
Closed -$392 – 1001
2016
Q4 		$392 Buy
3,200
+800
+33% +$97.9K 0.09% 296
2016
Q3 		$294K Buy
+2,400
New +$309K 0.06% 386

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Boothbay Fund Management's ALXN Position: Q3 2021 in Review

Boothbay Fund Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 52,296 shares — an estimated $9.61M sold.

Boothbay Fund Management first reported a position in ALXN in Q3 2016 and held it in 9 quarters. The position peaked at $9.61M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Boothbay Fund Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 52,296 Alexion Pharmaceuticals shares in Q3 2021, an estimated $9.61M.
  • Boothbay Fund Management first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 9 quarters.
  • Boothbay Fund Management's Alexion Pharmaceuticals position peaked at $9.61M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Boothbay Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.